Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver save search
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
Published: 2023-02-01 (Crawled : 15:00) - biospace.com/
MIRO | $3.35 5.44% 20K
|
Professional, Scientific, and T...
|
| O: -0.57%
H: 5.19%
C: -9.8%
BAX | $46.68 -0.7% -0.17% 4.7M
|
Health Technology
|
| O: 0.44%
H: 1.04%
C: 0.85%
care research liver for agreement
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Published: 2023-01-24 (Crawled : 13:20) - globenewswire.com
GALT A | $1.31 9.17% 8.4% 210K
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -0.89%
liver therapeutics
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ICPT A | $19.03 -0.63% -0.63% 450K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment fda fibrosis drug liver for application nash
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | $15.97 1.46% 0.0% 3.5M
|
Health Technology
|
| O: 1.3%
H: 0.38%
C: -0.19%
ARWR | $36.76 -0.68% -0.68% 610K
|
Health Technology
|
| O: -19.72%
H: 3.16%
C: 0.77%
liver disease topline results study
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Published: 2023-01-09 (Crawled : 11:00) - biospace.com/
ALBO | $44.96 0.92% 0.91% 510K
|
Health Technology
|
| O: 91.65%
H: 0.0%
C: 0.0%
rare liver acquire disease for growth
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
MDGL | $280.15 -2.12% -2.17% 290K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: 0.0%
treatment fibrosis liver for trial positive results nash
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
Published: 2023-01-04 (Crawled : 14:20) - biospace.com/
ICPT A | $19.03 -0.63% -0.63% 450K
|
Health Technology
| Email alert
Add to watchlist
fibrosis liver conference nash study
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
CMMB | $2.25 2.74% 2.67% 37K
|
Manufacturing
|
| O: 57.84%
H: 0.0%
C: 0.0%
cm-101 fibrosis liver biomarker trial results nash
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
Published: 2022-12-23 (Crawled : 13:00) - globenewswire.com
ICPT A | $19.03 -0.63% -0.63% 450K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
fda fibrosis drug liver for application nash
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Published: 2022-12-20 (Crawled : 12:20) - globenewswire.com
ALT A | $15.17 0.86% 0.86% 1.2M
|
Commercial Services
|
| O: -15.81%
H: 0.0%
C: 0.0%
liver disease topline trial positive results
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $280.15 -2.12% -2.17% 290K
|
Health Technology
|
| O: 229.23%
H: 0.0%
C: 0.0%
treatment fibrosis liver for topline trial positive results nash
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Published: 2022-12-16 (Crawled : 12:00) - globenewswire.com
ADAG | $1.92 4.35% 4.17% 22K
|
Manufacturing
|
| O: 9.16%
H: 0.0%
C: 0.0%
adg126 safebody liver for collaboration trial cancer
Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer
Published: 2022-12-14 (Crawled : 18:00) - biospace.com/
NEOS | $1.15 0%
|
Health Technology
| Email alert
Add to watchlist
ongoing liver trial therapeutics response cancer
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
Published: 2022-12-08 (Crawled : 00:00) - globenewswire.com
ICPT A | $19.03 -0.63% -0.63% 450K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
liver disease study
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $1.3 -4.41% -4.62% 41K
|
|
| O: 0.0%
H: 8.56%
C: 3.59%
liver disease for topline trial therapeutics positive results
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Published: 2022-12-05 (Crawled : 14:00) - globenewswire.com
HEPA | $0.8155 4.89% 4.66% 560K
|
Health Technology
|
| O: 5.6%
H: 6.63%
C: -0.88%
pharmaceuticals liver trial
Zhongchao Inc. Established SID Liver Cancer Comprehensive-Disciplinary Physician Education Platform
Published: 2022-12-05 (Crawled : 13:00) - prnewswire.com
ZCMD | $1.12 -1.35% 4.4K
|
Commercial Services
|
| O: 0.0%
H: 0.0%
C: -1.01%
liver education cancer platform
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
NVO | $136.79 3.36% 1.17% 1.8M
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
DTIL | $1.24 2.48% 2.42% 460K
|
Health Technology
|
| O: -5.38%
H: 4.55%
C: 3.79%
treatment rare liver for
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Published: 2022-11-17 (Crawled : 00:00) - globenewswire.com
GNFT | $4.5 -1.11% 4.5K
|
Health Technology
| Email alert
Add to watchlist
day liver
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
Published: 2022-11-07 (Crawled : 13:20) - biospace.com/
AKRO M | $47.95 0.5% 0.5% 340K
|
Health Technology
|
| O: -4.35%
H: 2.39%
C: -3.12%
meeting liver for therapeutics presentation today study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.